Cancer statistics, 2022.
CA Cancer J Clin. 72: 7-33Mosele F. Stefanovska B. Lusque A. et al.Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Ann Oncol. 31: 377-386National Comprehensive Cancer Network. Hepatobiliary Cancers.(Version 1.2022).
() ()Gallbladder cancer: epidemiology and outcome.
Clin Epidemiol. 6: 99-109Henley S.J. Weir H.K. Jim M.A. et al.Gallbladder Cancer Incidence and Mortality, United States 1999-2011.
Cancer Epidemiol biomarkers Prev. 24: 1319-1326Varshney S. Butturini G. Gupta R.Incidental carcinoma of the gallbladder.
Eur J Surg Oncol. 28: 4-10Duffy A. Capanu M. Abou-Alfa G.K. et al.Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).
J Surg Oncol. 98: 485-489Management of cancer gallbladder found as a surprise on a resected gallbladder specimen.
J Surg Oncol. 93: 690-698Incidence of Cholangiocarcinoma in the USA from 2001 to 2015: A US Cancer Statistics Analysis of 50 States.
Cureus. 11: e3962Shaib Y.H. Davila J.A. McGlynn K. et al.Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?.
J Hepatol. 40: 472-477Adenocarcinoma of the Hepatic Duct at Its Bifurcation within the Porta Hepatis. An Unusual Tumor with Distinctive Clinical and Pathological Features.
Am J Med. 38: 241-256Sutton T.L. Walker B.S. Radu S. et al.Degree of biliary tract violation during treatment of gallbladder adenocarcinoma is independently associated with development of peritoneal carcinomatosis.
J Surg Oncol. 124: 581-588Benson A.B. D'Angelica M.I. Abbott D.E. et al.Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 19: 541-565Okami J. Dono K. Sakon M. et al.Patterns of regional lymph node involvement in intrahepatic cholangiocarcinoma of the left lobe.
J Gastrointest Surg. 7: 850-856Bismuth H. Nakache R. Diamond T.Management strategies in resection for hilar cholangiocarcinoma.
Ann Surg. 215: 31-38Aloia T.A. Jarufe N. Javle M. et al.Gallbladder cancer: expert consensus statement.
HPB (Oxford). 17: 681-690Agarwal A.K. Kalayarasan R. Javed A. et al.The role of staging laparoscopy in primary gall bladder cancer--an analysis of 409 patients: a prospective study to evaluate the role of staging laparoscopy in the management of gallbladder cancer.
Ann Surg. 258: 318-323Fuks D. Regimbeau J.M. Le Treut Y.P. et al.Incidental gallbladder cancer by the AFC-GBC-2009 Study Group.
World J Surg. 35: 1887-1897Araida T. Higuchi R. Hamano M. et al.Hepatic resection in 485 R0 pT2 and pT3 cases of advanced carcinoma of the gallbladder: results of a Japanese Society of Biliary Surgery survey--a multicenter study.
J Hepatobiliary Pancreat Surg. 16: 204-215D'Angelica M. Dalal K.M. DeMatteo R.P. et al.Analysis of the extent of resection for adenocarcinoma of the gallbladder.
Ann Surg Oncol. 16: 806-816Maker A.V. Butte J.M. Oxenberg J. et al.Is port site resection necessary in the surgical management of gallbladder cancer?.
Ann Surg Oncol. 19: 409-417Edge S.B.M.B. Frederick L.G.American Joint Committee on cancer (AJCC) staging Handbook: from the AJCC cancer staging Manual.
8th edition. American Cancer Society, Cham, SwitzerlandIto H. Ito K. D'Angelica M. et al.Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment.
Ann Surg. 254: 320-325de Jong M.C. Nathan H. Sotiropoulos G.C. et al.Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.
J Clin Oncol. 29: 3140-3145Spolverato G. Yakoob M.Y. Kim Y. et al.The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma.
Ann Surg Oncol. 22: 4020-4028Response to the Comment on "Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis.
Ann Surg. 274: e743Zhang X.F. Xue F. Dong D.H. et al.Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis.
Ann Surg. 274: e1187-e1195Jarnagin W.R. Fong Y. DeMatteo R.P. et al.Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.
Ann Surg. 234 (): 507-517Jain V. Krishnamurthy G. Kumar H. et al.Anatomical Basis of Routine Caudate Lobe Resections in Hilar Cholangiocarcinoma.
J Gastrointest Surg. 25: 2114-2115Wahab M.A. Sultan A.M. Salah T. et al.Caudate lobe resection with major hepatectomy for central cholangiocarcinoma: is it of value?.
Hepatogastroenterology. 59: 321-324Birgin E. Rasbach E. Reissfelder C. et al.A systematic review and meta-analysis of caudate lobectomy for treatment of hilar cholangiocarcinoma.
Eur J Surg Oncol. 46: 747-753Lamarca A. Barriuso J. McNamara M.G. et al.Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
J Hepatol. 73: 170-185Valle J.W. Kelley R.K. Nervi B. et al.Biliary tract cancer.
Lancet. 397: 428-444Zhu A.X. Macarulla T. Javle M.M. et al.Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
JAMA Oncol. 7: 1669-1677Abou-Alfa G.K. Sahai V. Hollebecque A. et al.Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Lancet Oncol. 21: 671-684Bekaii-Saab T.S. Valle J.W. Van Cutsem E. et al.FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.
Future Oncol. 16: 2385-2399Jarnagin W.R. Ruo L. Little S.A. et al.Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies.
Cancer. 98: 1689-1700Doussot A. Gonen M. Wiggers J.K. et al.Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models.
J Am Coll Surg. 223: 493-505 e2Valle J. Wasan H. Palmer D.H. et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
N Engl J Med. 362: 1273-1281Edeline J. Benabdelghani M. Bertaut A. et al.Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.
J Clin Oncol. 37: 658-667Primrose J.N. Fox R.P. Palmer D.H. et al.Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
Lancet Oncol. 20: 663-673Ebata T. Hirano S. Konishi M. et al.Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.
Br J Surg. 105: 192-202Ben-Josef E. Guthrie K.A. El-Khoueiry A.B. et al.SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
J Clin Oncol. 33: 2617-2622Saluja S.S. Nekarakanti P.K. Mishra P.K. et al.Prospective Randomized Controlled Trial Comparing Adjuvant Chemotherapy vs. No Chemotherapy for Patients with Carcinoma of Gallbladder Undergoing Curative Resection.
J Gastrointest Surg. 26: 398-407Nakachi K. Konishi M. Ikeda M. et al.A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT).
Jpn J Clin Oncol. 48: 392-395Ikeda M. Nakachi K. Konishi M. et al.Adjuvant S-1 versus observation in curatively resected biliary tract cancer: A phase III trial (JCOG1202: ASCOT).
J Clin Oncol. 40https://doi.org/10.1200/JCO.2022.40.4_suppl.382):382Deutsche Krebshilfe E.V. BGCRUAG-ITGDHC, (DHCG) CCG. Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After CurativeIntent Resection of Biliary Tract Cancer (ACTICCA-1).
() ()Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer (OPT-IN EA2197).
() ()Maithel S.K. Javle M.M. Mahipal A. et al.NEO-GAP: A phase II single-arm prospective feasibility study of neoadjuvant gemcitabine/cisplatin/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma.
J Clin Oncol. : 4097Cercek A. Boerner T. Tan B.R. et al.Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
JAMA Oncol. 6: 60-67
留言 (0)